DOCSLIB.ORG

Mouse Smarce1 Conditional Knockout Project (CRISPR/Cas9)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mouse Smarce1 Conditional Knockout Project (CRISPR/Cas9) https://www.alphaknockout.com Mouse Smarce1 Conditional Knockout Project (CRISPR/Cas9) Objective: To create a Smarce1 conditional knockout Mouse model (C57BL/6J) by CRISPR/Cas-mediated genome engineering. Strategy summary: The Smarce1 gene (NCBI Reference Sequence: NM_020618 ; Ensembl: ENSMUSG00000037935 ) is located on Mouse chromosome 11. 11 exons are identified, with the ATG start codon in exon 2 and the TAA stop codon in exon 11 (Transcript: ENSMUST00000103133). Exon 5~7 will be selected as conditional knockout region (cKO region). Deletion of this region should result in the loss of function of the Mouse Smarce1 gene. To engineer the targeting vector, homologous arms and cKO region will be generated by PCR using BAC clone RP23-96J15 as template. Cas9, gRNA and targeting vector will be co-injected into fertilized eggs for cKO Mouse production. The pups will be genotyped by PCR followed by sequencing analysis. Note: Mice homozygous for a knock-out allele exhibit prenatal lethality. Exon 5 starts from about 12.73% of the coding region. The knockout of Exon 5~7 will result in frameshift of the gene. The size of intron 4 for 5'-loxP site insertion: 4302 bp, and the size of intron 7 for 3'-loxP site insertion: 3933 bp. The size of effective cKO region: ~2016 bp. The cKO region does not have any other known gene. Page 1 of 7 https://www.alphaknockout.com Overview of the Targeting Strategy Wildtype allele 5' gRNA region gRNA region 3' 1 5 6 7 11 Targeting vector Targeted allele Constitutive KO allele (After Cre recombination) Legends Exon of mouse Smarce1 Homology arm cKO region loxP site Page 2 of 7 https://www.alphaknockout.com Overview of the Dot Plot Window size: 10 bp Forward Reverse Complement Sequence 12 Note: The sequence of homologous arms and cKO region is aligned with itself to determine if there are tandem repeats. No significant tandem repeat is found in the dot plot matrix. So this region is suitable for PCR screening or sequencing analysis. Overview of the GC Content Distribution Window size: 300 bp Sequence 12 Summary: Full Length(8516bp) | A(27.84% 2371) | C(19.74% 1681) | T(30.82% 2625) | G(21.59% 1839) Note: The sequence of homologous arms and cKO region is analyzed to determine the GC content. No significant high GC-content region is found. So this region is suitable for PCR screening or sequencing analysis. Page 3 of 7 https://www.alphaknockout.com BLAT Search Results (up) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN ----------------------------------------------------------------------------------------------- browser details YourSeq 3000 1 3000 3000 100.0% chr11 - 99220986 99223985 3000 browser details YourSeq 41 1501 1555 3000 97.8% chr7 - 87178077 87178351 275 browser details YourSeq 24 2685 2709 3000 100.0% chr12 + 66099250 66099275 26 Note: The 3000 bp section upstream of Exon 5 is BLAT searched against the genome. No significant similarity is found. BLAT Search Results (down) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN ----------------------------------------------------------------------------------------------- browser details YourSeq 3000 1 3000 3000 100.0% chr11 - 99215970 99218969 3000 browser details YourSeq 472 112 1092 3000 88.3% chr1 - 155404975 155405990 1016 browser details YourSeq 418 443 1092 3000 87.1% chr11 - 94551858 94552418 561 browser details YourSeq 406 442 1090 3000 86.6% chr5 + 144007304 144007966 663 browser details YourSeq 400 444 1087 3000 87.7% chr17 - 47406081 47406745 665 browser details YourSeq 397 441 1092 3000 88.1% chr5 + 116000890 116001439 550 browser details YourSeq 396 444 1085 3000 89.1% chr17 + 15509408 15510071 664 browser details YourSeq 391 441 1092 3000 89.1% chr16 + 35762365 35763032 668 browser details YourSeq 390 441 1092 3000 86.0% chr13 - 40044957 40045520 564 browser details YourSeq 389 441 1092 3000 86.6% chr12 - 13395618 13396180 563 browser details YourSeq 382 441 1092 3000 86.1% chr1 - 23394992 23395554 563 browser details YourSeq 381 441 1069 3000 88.6% chr2 - 125127983 125128635 653 browser details YourSeq 381 441 1091 3000 85.0% chr15 - 41261124 41261685 562 browser details YourSeq 380 441 1092 3000 87.5% chr9 - 78028545 78029222 678 browser details YourSeq 379 441 1092 3000 85.9% chr5 - 33913774 33914328 555 browser details YourSeq 379 441 1092 3000 84.7% chr18 + 12560065 12560625 561 browser details YourSeq 378 441 1091 3000 84.5% chr5 + 138122127 138122686 560 browser details YourSeq 378 442 1091 3000 89.7% chr14 + 87394587 87395278 692 browser details YourSeq 377 441 1092 3000 85.4% chr17 - 87028849 87029404 556 browser details YourSeq 377 441 1092 3000 84.0% chr6 + 24475966 24476528 563 Note: The 3000 bp section downstream of Exon 7 is BLAT searched against the genome. No significant similarity is found. Page 4 of 7 https://www.alphaknockout.com Gene and protein information: Smarce1 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member 1 [ Mus musculus (house mouse) ] Gene ID: 57376, updated on 12-Aug-2019 Gene summary Official Symbol Smarce1 provided by MGI Official Full Name SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member 1 provided by MGI Primary source MGI:MGI:1927347 See related Ensembl:ENSMUSG00000037935 Gene type protein coding RefSeq status VALIDATED Organism Mus musculus Lineage Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; Murinae; Mus; Mus Also known as Baf27; 2810417B20Rik; 5830412H02Rik; 9030408N19Rik Expression Broad expression in CNS E11.5 (RPKM 73.8), CNS E14 (RPKM 55.2) and 23 other tissues See more Orthologs human all Genomic context Location: 11; 11 D See Smarce1 in Genome Data Viewer Exon count: 11 Annotation release Status Assembly Chr Location 108 current GRCm38.p6 (GCF_000001635.26) 11 NC_000077.6 (99209047..99231017, complement) Build 37.2 previous assembly MGSCv37 (GCF_000001635.18) 11 NC_000077.5 (99070361..99092331, complement) Chromosome 11 - NC_000077.6 Page 5 of 7 https://www.alphaknockout.com Transcript information: This gene has 6 transcripts Gene: Smarce1 ENSMUSG00000037935 Description SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member 1 [Source:MGI Symbol;Acc:MGI:1927347] Gene Synonyms 2810417B20Rik, 5830412H02Rik, 9030408N19Rik, BAF57 Location Chromosome 11: 99,209,047-99,231,017 reverse strand. GRCm38:CM001004.2 About this gene This gene has 6 transcripts (splice variants), 312 orthologues, 33 paralogues, is a member of 1 Ensembl protein family and is associated with 1 phenotype. Transcripts Name Transcript ID bp Protein Translation ID Biotype CCDS UniProt Flags Smarce1-201 ENSMUST00000103133.3 2919 411aa ENSMUSP00000099422.3 Protein coding CCDS25374 O54941 TSL:1 GENCODE basic APPRIS P1 Smarce1-202 ENSMUST00000128215.1 3117 No protein - lncRNA - - TSL:1 Smarce1-204 ENSMUST00000135040.7 761 No protein - lncRNA - - TSL:1 Smarce1-206 ENSMUST00000156160.1 610 No protein - lncRNA - - TSL:2 Smarce1-205 ENSMUST00000155062.1 481 No protein - lncRNA - - TSL:2 Smarce1-203 ENSMUST00000128707.7 456 No protein - lncRNA - - TSL:5 41.97 kb Forward strand 99.20Mb 99.21Mb 99.22Mb 99.23Mb 99.24Mb Contigs < AL590991.14 Genes (Comprehensive set... < Smarce1-201protein coding < Krt222-202protein coding < Smarce1-206lncRNA < Smarce1-205lncRNA < Smarce1-202lncRNA < Krt222-201protein coding < Smarce1-204lncRNA < Krt222-203lncRNA < Smarce1-203lncRNA Regulatory Build 99.20Mb 99.21Mb 99.22Mb 99.23Mb 99.24Mb Reverse strand 41.97 kb Regulation Legend CTCF Enhancer Open Chromatin Promoter Promoter Flank Gene Legend Protein Coding merged Ensembl/Havana Ensembl protein coding Non-Protein Coding RNA gene Page 6 of 7 https://www.alphaknockout.com Transcript: ENSMUST00000103133 < Smarce1-201protein coding Reverse strand 21.97 kb ENSMUSP00000099... MobiDB lite Low complexity (Seg) Coiled-coils (Ncoils) Superfamily High mobility group box domain superfamily SMART High mobility group box domain Pfam High mobility group box domain PROSITE profiles High mobility group box domain PANTHER PTHR46232:SF2 SWI/SNF complex subunit BAF57 Gene3D High mobility group box domain superfamily CDD cd01390 All sequence SNPs/i... Sequence variants (dbSNP and all other sources) Variant Legend stop gained missense variant synonymous variant Scale bar 0 40 80 120 160 200 240 280 320 360 411 We wish to acknowledge the following valuable scientific information resources: Ensembl, MGI, NCBI, UCSC. Page 7 of 7.
Load more

Recommended publications
  • Mediator of DNA Damage Checkpoint 1 (MDC1) Is a Novel Estrogen Receptor Co-Regulator in Invasive 6 Lobular Carcinoma of the Breast 7 8 Evelyn K
    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.16.423142; this version posted December 16, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. 1 Running Title: MDC1 co-regulates ER in ILC 2 3 Research article 4 5 Mediator of DNA damage checkpoint 1 (MDC1) is a novel estrogen receptor co-regulator in invasive 6 lobular carcinoma of the breast 7 8 Evelyn K. Bordeaux1+, Joseph L. Sottnik1+, Sanjana Mehrotra1, Sarah E. Ferrara2, Andrew E. Goodspeed2,3, James 9 C. Costello2,3, Matthew J. Sikora1 10 11 +EKB and JLS contributed equally to this project. 12 13 Affiliations 14 1Dept. of Pathology, University of Colorado Anschutz Medical Campus 15 2Biostatistics and Bioinformatics Shared Resource, University of Colorado Comprehensive Cancer Center 16 3Dept. of Pharmacology, University of Colorado Anschutz Medical Campus 17 18 Corresponding author 19 Matthew J. Sikora, PhD.; Mail Stop 8104, Research Complex 1 South, Room 5117, 12801 E. 17th Ave.; Aurora, 20 CO 80045. Tel: (303)724-4301; Fax: (303)724-3712; email: [email protected]. Twitter: 21 @mjsikora 22 23 Authors' contributions 24 MJS conceived of the project. MJS, EKB, and JLS designed and performed experiments. JLS developed models 25 for the project. EKB, JLS, SM, and AEG contributed to data analysis and interpretation. SEF, AEG, and JCC 26 developed and performed informatics analyses. MJS wrote the draft manuscript; all authors read and revised the 27 manuscript and have read and approved of this version of the manuscript.
    [Show full text]
  • Inactivation of the PBRM1 Tumor Suppressor Gene Amplifies
    Inactivation of the PBRM1 tumor suppressor gene − − amplifies the HIF-response in VHL / clear cell renal carcinoma Wenhua Gaoa, Wei Lib,c, Tengfei Xiaoa,b,c, Xiaole Shirley Liub,c, and William G. Kaelin Jr.a,d,1 aDepartment of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115; bCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215; cDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health, Boston, MA 02115; and dHoward Hughes Medical Institute, Chevy Chase, MD 20815 Contributed by William G. Kaelin, Jr., December 1, 2016 (sent for review October 31, 2016; reviewed by Charles W. M. Roberts and Ali Shilatifard) Most clear cell renal carcinomas (ccRCCs) are initiated by somatic monolayer culture and in soft agar (10). These effects were not, inactivation of the VHL tumor suppressor gene. The VHL gene prod- however, proven to be on-target, and were not interrogated in uct, pVHL, is the substrate recognition unit of an ubiquitin ligase vivo. As a step toward understanding the role of BAF180 in that targets the HIF transcription factor for proteasomal degrada- ccRCC, we asked whether BAF180 participates in the canonical tion; inappropriate expression of HIF target genes drives renal car- PBAF complex in ccRCC cell lines and whether loss of BAF180 cinogenesis. Loss of pVHL is not sufficient, however, to cause ccRCC. measurably alters ccRCC behavior in cell culture and in mice. Additional cooperating genetic events, including intragenic muta- tions and copy number alterations, are required.
    [Show full text]
  • SMARCE1 Mutations in Pediatric Clear Cell Meningioma: Case Report
    PEDIATRICS CASE REPORT J Neurosurg Pediatr 16:296–300, 2015 SMARCE1 mutations in pediatric clear cell meningioma: case report Linton T. Evans, MD,1 Jack Van Hoff, MD,2,4,5 William F. Hickey, MD,3,4 Miriam J. Smith, PhD,6 D. Gareth Evans, MD,6 William G. Newman, MD, PhD,6 and David F. Bauer, MD1,2,4,5 1Section of Neurosurgery, 2Department of Pediatrics, and 3Department of Pathology, Dartmouth-Hitchcock Medical Center; 4Norris Cotton Cancer Center; 5Children’s Hospital at Dartmouth-Hitchcock, Lebanon, New Hampshire; and 6Manchester Centre for Genomic Medicine, Manchester Academic Health Sciences Centre (MAHSC), St. Mary’s Hospital, University of Manchester, United Kingdom Clear cell meningioma (CCM) is an uncommon variant of meningioma. The authors describe a case of a pediatric CCM localized to the lumbar spine. After resection, sequencing revealed an inactivating mutation in the SWI/SNF chromatin remodeling complex subunit SMARCE1, with loss of the second allele in the tumor. The authors present a literature review of this mutation that is associated with CCM and a family history of spine tumors. http://thejns.org/doi/abs/10.3171/2015.3.PEDS14417 KEY WORDS clear cell meningioma; SMARCE1; SWI/SNF; oncology LEAR cell meningioma (CCM) is a rare histopatho- of a SMARCE1 mutation and loss of heterozygosity in logical variant originally described in 1990. This a 3-year-old boy with an intraspinal CCM and a relative subtype is estimated to account for less than 1% of with a known spinal tumor. meningiomasC but is frequently difficult to treat. Despite a benign histological appearance, these tumors exhibit Case Report aggressive behavior with up to 60% recurring following resection.
    [Show full text]
  • Identification and Characterization of Novel Potentially Oncogenic Mutations in the Human Gene in a Breast Cancer Patient M
    Identification and characterization of novel potentially oncogenic mutations in the human gene in a breast cancer patient M. Ángeles Villaronga, Irene López-Mateo, Linn Markert, Enrique Espinosa, Juan Ángel Fresno Vara, Borja Belandia To cite this version: M. Ángeles Villaronga, Irene López-Mateo, Linn Markert, Enrique Espinosa, Juan Ángel Fresno Vara, et al.. Identification and characterization of novel potentially oncogenic mutations in the human gene in a breast cancer patient. Breast Cancer Research and Treatment, Springer Verlag, 2011, 128 (3), pp.891-898. 10.1007/s10549-011-1492-4. hal-00629080 HAL Id: hal-00629080 https://hal.archives-ouvertes.fr/hal-00629080 Submitted on 5 Oct 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Identification and characterization of novel potentially oncogenic mutations in the human BAF57 gene in a breast cancer patient 1* 1* 1 2 Mª Ángeles Villaronga , Irene López-Mateo , Linn Markert , Enrique Espinosa , Juan Ángel Fresno-Vara3 and Borja Belandia1 1Department of Cancer Biology, Instituto de Investigaciones Biomédicas Alberto Sols, CSIC-UAM, Arturo Duperier 4, 28029 Madrid, Spain 2Service of Oncology, IdiPAZ, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain 3Laboratory of Molecular Pathology & Oncology, IdiPAZ, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain *Mª Ángeles Villaronga and Irene López-Mateo contributed equally to this study and should be considered as co-first authors.
    [Show full text]
  • Anti- SMARCE1 Antibody
    anti- SMARCE1 antibody Product Information Catalog No.: FNab08015 Size: 100μg Form: liquid Purification: Protein A+G purification Purity: ≥95% as determined by SDS-PAGE Host: Mouse Clonality: monoclonal Clone ID: 1G10 IsoType: IgG1 Storage: PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20℃ for 12 months (Avoid repeated freeze / thaw cycles.) Background Involved in transcriptional activation and repression of select genes by chromatin remodeling(alteration of DNA-nucleosome topology). Belongs to the neural progenitors-specific chromatin remodeling complex(npBAF complex) and the neuron-specific chromatin remodeling complex(nBAF complex). During neural development a switch from a stem/progenitor to a post- mitotic chromatin remodeling mechanism occurs as neurons exit the cell cycle and become committed to their adult state. The transition from proliferating neural stem/progenitor cells to post-mitotic neurons requires a switch in subunit composition of the npBAF and nBAF complexes. As neural progenitors exit mitosis and differentiate into neurons, npBAF complexes which contain ACTL6A/BAF53A and PHF10/BAF45A, are exchanged for homologous alternative ACTL6B/BAF53B and DPF1/BAF45B or DPF3/BAF45C subunits in neuron-specific complexes(nBAF). The npBAF complex is essential for the self-renewal/proliferative capacity of the multipotent neural stem cells. The nBAF complex along with CREST plays a role regulating the activity of genes essential for dendrite growth(By similarity). Required for the coactivation of estrogen responsive promoters by Swi/Snf complexes and the SRC/p160 family of histone acetyltransferases(HATs). Also specifically interacts with the CoREST corepressor resulting in repression of neuronal specific gene promoters in non-neuronal cells.
    [Show full text]
  • SNF5/INI1 Deficiency Redefines Chromatin Remodeling Complex Composition During Tumor Development
    Published OnlineFirst July 9, 2014; DOI: 10.1158/1541-7786.MCR-14-0005 Molecular Cancer Chromatin, Gene, and RNA Regulation Research SNF5/INI1 Deficiency Redefines Chromatin Remodeling Complex Composition during Tumor Development Darmood Wei1, Dennis Goldfarb2, Shujie Song3,4, Courtney Cannon4,5, Feng Yan4, Donastas Sakellariou- Thompson4, Michael Emanuele4,5, Michael B. Major4,6, Bernard E. Weissman4,7, and Yasumichi Kuwahara4,8 Abstract Malignant rhabdoid tumors (MRT), a pediatric cancer that most frequently appears in the kidney and brain, generally lack SNF5 (SMARCB1/INI1), a subunit of the SWI/SNF chromatin-remodeling complex. Recent studies have established that multiple SWI/SNF complexes exist due to the presence or absence of different complex members. Therefore, the effect of SNF5 loss upon SWI/SNF complex formation was investigated in human MRT cells. MRT cells and primary human tumors exhibited reduced levels of many complex proteins. Furthermore, reexpression of SNF5 increased SWI/SNF complex protein levels without concomitant increases in mRNA. Proteomic analysis, using mass spectrometry, of MRT cells before and after SNF5 reexpression indicated the recruitment of different components into the complex along with the expulsion of others. IP–Western blotting confirmed these results and demonstrated similar changes in other MRT cell lines. Finally, reduced expression of SNF5 in normal human fibroblasts led to altered levels of these same complex members. These data establish that SNF5 loss during MRT development alters the repertoire of available SWI/SNF complexes, generally disrupting those associated with cellular differentiation. These findings support a model where SNF5 inactivation blocks the conversion of growth-promoting SWI/SNF complexes to differentiation-inducing ones.
    [Show full text]
  • A Role for SMARCB1 in Synovial Sarcomagenesis Reveals That SS18-SSX Induces Canonical BAF Destruction
    Author Manuscript Published OnlineFirst on June 2, 2021; DOI: 10.1158/2159-8290.CD-20-1219 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. SMARCB1 in Synovial Sarcomagenesis 1 A role for SMARCB1 in synovial sarcomagenesis reveals that SS18-SSX induces canonical BAF destruction Jinxiu Li*1,2,3, Timothy S. Mulvihill*2,3, Li Li1,2,3, Jared J. Barrott1,2,3, Mary L. Nelson1,2,3, Lena Wagner6, Ian C. Lock1,2,3, Amir Pozner1,2,3, Sydney Lynn Lambert1,2,3, Benjamin B. Ozenberger1,2,3, Michael B. Ward3,4, Allie H. Grossmann3,4, Ting Liu3,4, Ana Banito6, Bradley R. Cairns2,3,5† and Kevin B. Jones1,2,3† 1Department of Orthopaedics, 2Department of Oncological Sciences, 3Huntsman Cancer Institute, 4Department of Pathology, 5Howard Hughes Medical Institute, University of Utah, Salt Lake City, Utah. 6Hopp Children’s Cancer Center (KiTZ), German Cancer Research Center (DFKZ), Heidelberg, Germany. *These authors contributed equally to this work. †These authors are co-corresponding authors. Please Address Correspondence to: Kevin B. Jones and Bradley R. Cairns Address: 2000 Circle of Hope Drive, Salt Lake City, UT 84112 Phone: 801-585-0300 Fax: 801-585-7084 Email: [email protected], [email protected] Running Title: SMARCB1 in Synovial Sarcomagenesis Key Words: SWI/SNF; Chromatin Remodeling; Mouse Genetic Model; Epigenetics; Biochemistry Financial Support: This work was supported by R01CA201396 (Jones and Cairns), U54CA231652 (Jones, Cairns, and Banito), and 2P30CA042014-31, from the National Cancer Institute (NCI/NIH), as well as the Paul Nabil Bustany Fund for Synovial Sarcoma Research (Jones), and the Sarcoma Foundation of America (Barrott).
    [Show full text]
  • High Yield of Pathogenic Germline Mutations Causative Or Likely Causative of the Cancer Phenotype in Selected Children with Cancer Illja J
    Published OnlineFirst January 19, 2018; DOI: 10.1158/1078-0432.CCR-17-1725 Personalized Medicine and Imaging Clinical Cancer Research High Yield of Pathogenic Germline Mutations Causative or Likely Causative of the Cancer Phenotype in Selected Children with Cancer Illja J. Diets1,2, Esme Waanders1,2,3, Marjolijn J. Ligtenberg1,2,4, Diede A.G. van Bladel1,2, Eveline J. Kamping1,2, Peter M. Hoogerbrugge3, Saskia Hopman5, Maran J. Olderode-Berends6, Erica H. Gerkes6, David A. Koolen1, Carlo Marcelis1, Gijs W. Santen7, Martine J. van Belzen7, Dylan Mordaunt8, Lesley McGregor8, Elizabeth Thompson8, Antonis Kattamis9, Agata Pastorczak10, Wojciech Mlynarski10, Denisa Ilencikova11, Anneke Vulto- van Silfhout1, Thatjana Gardeitchik1, Eveline S. de Bont12, Jan Loeffen13, Anja Wagner14, Arjen R. Mensenkamp1, Roland P. Kuiper1,2,3, Nicoline Hoogerbrugge1,2, and Marjolijn C. Jongmans1,2,3,5 Abstract Purpose: In many children with cancer and characteristics Results: Four patients carried causative mutations in a known suggestive of a genetic predisposition syndrome, the genetic cause cancer-predisposing gene: TP53 and DICER1 (n ¼ 3). In another 4 is still unknown. We studied the yield of pathogenic mutations by patients, exome sequencing revealed mutations causing syn- applying whole-exome sequencing on a selected cohort of chil- dromes that might have contributed to the malignancy (EP300- dren with cancer. based Rubinstein–Taybi syndrome, ARID1A-based Coffin–Siris Experimental Design: To identify mutations in known and syndrome, ACTB-based Baraitser–Winter syndrome, and EZH2- novel cancer-predisposing genes, we performed trio-based based Weaver syndrome). In addition, we identified two genes, whole-exome sequencing on germline DNA of 40 selected KDM3B and TYK2, which are possibly involved in genetic cancer children and their parents.
    [Show full text]
  • Autism and Cancer Share Risk Genes, Pathways, and Drug Targets
    TIGS 1255 No. of Pages 8 Forum Table 1 summarizes the characteristics of unclear whether this is related to its signal- Autism and Cancer risk genes for ASD that are also risk genes ing function or a consequence of a second for cancers, extending the original finding independent PTEN activity, but this dual Share Risk Genes, that the PI3K-Akt-mTOR signaling axis function may provide the rationale for the (involving PTEN, FMR1, NF1, TSC1, and dominant role of PTEN in cancer and Pathways, and Drug TSC2) was associated with inherited risk autism. Other genes encoding common Targets for both cancer and ASD [6–9]. Recent tumor signaling pathways include MET8[1_TD$IF],[2_TD$IF] genome-wide exome-sequencing studies PTK7, and HRAS, while p53, AKT, mTOR, Jacqueline N. Crawley,1,2,* of de novo variants in ASD and cancer WNT, NOTCH, and MAPK are compo- Wolf-Dietrich Heyer,3,4 and have begun to uncover considerable addi- nents of signaling pathways regulating Janine M. LaSalle1,4,5 tional overlap. What is surprising about the the nuclear factors described above. genes in Table 1 is not necessarily the Autism is a neurodevelopmental number of risk genes found in both autism Autism is comorbid with several mono- and cancer, but the shared functions of genic neurodevelopmental disorders, disorder, diagnosed behaviorally genes in chromatin remodeling and including Fragile X (FMR1), Rett syndrome by social and communication genome maintenance, transcription fac- (MECP2), Phelan-McDermid (SHANK3), fi de cits, repetitive behaviors, tors, and signal transduction pathways 15q duplication syndrome (UBE3A), and restricted interests. Recent leading to nuclear changes [7,8].
    [Show full text]
  • 794776V1.Full.Pdf
    bioRxiv preprint doi: https://doi.org/10.1101/794776; this version posted October 6, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Novel functional insights revealed by distinct protein-protein interactions of the residual SWI/SNF complex in SMARCA4-deficient small cell carcinoma of the ovary, hypercalcemic type Elizabeth A. Raupach1*, Krystine Garcia-Mansfield2*, Ritin Sharma2, Apurva M. Hegde2, Victoria David- Dirgo2, Yemin Wang3,4, Chae Young Shin3,4, Lan V. Tao4, Salvatore J. Facista1, Rayvon Moore5, Jessica D. Lang1, Victoria L. Zismann1, Krystal A. Orlando5,6, Monique Spillman7, Anthony N. Karnezis8, Lynda B. Bennett9, David G. Huntsman3,4,10, Jeffrey M. Trent1, William P. D. Hendricks1, Bernard E. Weissman5,6, and Patrick Pirrotte2‡ *These authors contributed equally to this work. 1: Integrated Cancer Genomics, Translational Genomics Research Institute, Phoenix, AZ, USA 2: Collaborative Center for Translational Mass Spectrometry, Translational Genomics Research Institute, Phoenix, AZ, USA 3: Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada 4: Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada 5: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA 6: Department of Pathology and Laboratory Medicine,
    [Show full text]
  • Regulatory Genetics of Single Nucleotide Polymorphisms
    UNIVERSITY OF CALIFORNIA, SAN DIEGO In Silico, In Vitro, In Vivo and In Populo: Regulatory Genetics of Single Nucleotide Polymorphisms in the Phenylethanolamine N-Methyltransferase Promoter A Dissertation submitted in partial satisfaction of the requirements for the degree Doctor of Philosophy in Bioinformatics by Juan Lorenzo Rodriguez Flores Committee in charge: Professor Daniel T. O’Connor, Chair Professor Vineet Bafna Professor Shankar Subramanian Professor Glenn Tesler Professor Wei Wang Professor Michael Ziegler 2009 Copyright Juan Lorenzo Rodriguez Flores, 2009 All rights reserved. The Dissertation of Juan Lorenzo Rodriguez Flores is approved, and it is acceptable in quality and form for publication on microfilm and electronically: ___________________________________________________ ___________________________________________________ ___________________________________________________ ___________________________________________________ ___________________________________________________ ___________________________________________________ Chair University of California, San Diego 2009 iii DEDICATION I dedicate this dissertation to my family. The Rodriguez, Flores, Quesada and Forastieri of Puerto Rico, a tribe whose history, accomplishments and adventures constantly remind me of who I am, where I came from and what I am capable of. I also dedicate this dissertation to Tatiana, who first danced with me the day I advanced to candidacy and who shortly after became my soulmate and the love of my life. She provided infinite support, motivation and nourishment for my graduation. iv EPIGRAPH We have been told we cannot do this by a chorus of cynics who will only grow louder and more dissonant in the weeks to come. We've been asked to pause for a reality check. We've been warned against offering ... false hope. But in the unlikely story that is America, there has never been anything false about hope...
    [Show full text]
  • A Genomic View of Estrogen Actions in Human Breast Cancer Cells by Expression Profiling of the Hormone-Responsive Transcriptome
    719 A genomic view of estrogen actions in human breast cancer cells by expression profiling of the hormone-responsive transcriptome Luigi Cicatiello1, Claudio Scafoglio1, Lucia Altucci1, Massimo Cancemi1, Guido Natoli1, Angelo Facchiano2, Giovanni Iazzetti3, Raffaele Calogero4, Nicoletta Biglia6, Michele De Bortoli5,7, Christian Sfiligoi7, Piero Sismondi6,7, Francesco Bresciani1 and Alessandro Weisz1 1Dipartimento di Patologia generale, Seconda Università degli Studi di Napoli, Vico L. De Crecchio 7, 80138 Napoli, Italy 2Istituto di Scienze dell’Alimentazione del Consiglio Nazionale delle Ricerche, Avellino, Italy 3Dipartimento di Genetica, Biologia generale e molecolare, Università di Napoli ‘Federico II’, Napoli, Italy 4Dipartimento di Scienze cliniche e biologiche, Università degli Studi di Torino, Torino, Italy 5Dipartimento di Scienze oncologiche, Università degli Studi di Torino, Torino, Italy 6Dipartimento di Discipline ostetriche e ginecologiche, Università degli Studi di Torino, Torino, Italy 7Laboratorio di Ginecologia oncologica, Istituto per la Ricerca e la Cura del Cancro, Candiolo, Italy (Requests for offprints should be addressed to A Weisz; Email: [email protected]) Abstract Estrogen controls key cellular functions of responsive cells including the ability to survive, replicate, communicate and adapt to the extracellular milieu. Changes in the expression of 8400 genes were monitored here by cDNA microarray analysis during the first 32 h of human breast cancer (BC) ZR-75·1 cell stimulation with a mitogenic dose of 17-estradiol, a timing which corresponds to completion of a full mitotic cycle in hormone-stimulated cells. Hierarchical clustering of 344 genes whose expression either increases or decreases significantly in response to estrogen reveals that the gene expression program activated by the hormone in these cells shows 8 main patterns of gene activation/inhibition.
    [Show full text]